肝细胞癌合并门静脉癌栓的治疗进展  

Recent progress in the treatment of hepatocellular carcinoma associated with portal vein tumor thrombosis

作　　者：杨胜利[1] 任伟新[1] YANG Shengli;REN Weixin(Department of Interventional Radiology,First Affiliated Hospital of Xinjiang Medical University,Urumqi,the Xinjiang Uygur Autonomous Region 830054,China)

机构地区：[1]新疆医科大学第一附属医院介入放射科,乌鲁木齐830054

出　　处：《介入放射学杂志》2022年第1期104-108,共5页Journal of Interventional Radiology

摘　　要：门静脉癌栓(PVTT)是肝细胞癌(HCC)常见的并发症之一,伴有PVTT的HCC患者,肝功能差,肝内外转移及合并门静脉高压的风险大,预后通常较差。西方指南推荐索拉非尼为标准的治疗方案。然而,临床上有很多种治疗方法可供选择,本文对各种疗法作一探讨,就目前热门的系统治疗、门静脉血管腔内治疗及局部治疗联合系统治疗的最新进展作一重点分析。Portal vein tumor thrombosis(PVTT)is one of the common complications of hepatocellular carcinoma(HCC).Clinically,Patients with HCC complicated by PVTT usually have a strong aggressive disease course,poor liver functions,high risk of intra-hepatic and extra-hepatic metastases,portal hypertension,and poor prognosis.The guidelines in Western countries recommend sorafenib as the standard treatment scheme.However,there are many therapeutic methods that are available to be adopted in the treatment of HCC complicated by PVTT.This paper aims to make a review about the recent advances in the treatment of HCC complicated by PVTT,focusing on the most popular systemic therapy,portal vein endovascular therapy and local treatment combined with systemic therapy.(J Intervent Radiol,2022,31:104-108)

关 键 词：门静脉癌栓 肝细胞肝癌 预后 

分 类 号：R735[医药卫生—肿瘤]